May. 12 at 10:55 AM
Wells Fargo y'day⬆️
$LQDA's PT to
$62 (was
$51), reiterated Overweight, ans said: Yutrepia appears to be disrupting the PAH/PH-ILD market, and we anticipate this level of growth continues through 2Q26.
$UTHR MNKD
$INSM
Wells Fargo added—We're raising our PT to
$62/shr as we lift our near-term Yutrepia est., and we now include risk-adjusted value for L606 in IPF.
Stock setup. Shares are up significantly on the day (+25.6% vs XBI of +0.03%), we think driven by the strong Yutrepia sales, which is concordant with weaker-than-expected Tyvaso. We think this has added conviction for Yutrepia to drive significant earnings growth. We believe Yutrepia is likely out-competing Tyvaso for new patients, and possibly also taking share from Tyvaso nebulizer. It doesn't seem likely that growth will slow near term, and therefore we expect further share capture in 2Q26.
